Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-11
2005-01-11
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S352000, C514S357000
Reexamination Certificate
active
06841565
ABSTRACT:
The invention provides methods for treating a patient with chronic lymphocytic leukemia of B cells (B-CLL). One method comprises administering to a patient with B-CLL, one or more benzamide derivatives, the benzamide derivatives including MS-275 and related compounds. Another method comprises administering to a patient with B-CLL, one or more of the benzamide derivatives, and additionally administering to the patient one or more antibodies immunospecific for 1D10 antigen. Additional methods for inducing apoptosis of B-CLL cells and for increasing expression of 1D10 antigen in B-CLL cells using the benzamide derivatives are also provided.
REFERENCES:
patent: 6129914 (2000-10-01), Weiner et al.
patent: 6174905 (2001-01-01), Suzuki et al.
patent: 6316435 (2001-11-01), Byrd et al.
patent: 6320078 (2001-11-01), Suzuki et al.
patent: 2002 256194 (2000-09-01), None
Database BIOSIS on STN, AN 2002:367448, Lucas et al., “MS-275 reduces viability and induces change inhistone acetylation in cells from patients with B-cellchronic lymphocytic leukemia”, Proceedings of the American Associate for Cancer Research Annual Meeting, Mar. 2002, vol. 43, pp 69, meeting abstract.
Database BIOSIS on STN, AN 2003:336100, Lucas et al., “MS-275 promotes apoptosis in cell from patient with B-cell chronic lymphocytic leukemia (B -CLL) concurrent with inhibition of histone deactylase”, Blood (2002) vol. 100k, No. 11, pp. Abstract No. 1500.
Byrd John C.
Grever Michael R.
Lucas David M.
Parthun Mark R.
Calfee Halter & Griswold LLP
Henley III Raymond J.
The Ohio State University
LandOfFree
Treatment of patients with chronic lymphocytic leukemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of patients with chronic lymphocytic leukemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of patients with chronic lymphocytic leukemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3433347